Altasciences, a Canada-based provider of early phase clinical research services, and ITR Laboratories, a nonclinical CRO, have formed a strategic alliance to offer clients a way to customize their drug development programs from lead candidate selection through to early stage clinical trials. This alliance facilitates working with a single integrated partner to bring drug candidates to proof-of-concept faster and reduce costs.
“Few organizations can offer an integrated early development solution which includes expertise in both nonclinical and clinical testing, along with personalized service. ITR and Altasciences are customer-centric, full-service companies that provide the necessary focused expertise from nonclinical studies to first-in-human and proof-of-concept clinical programs, which we believe will benefit our sponsors with customized turn-key solutions,” said Chris Perkin, CEO at Altasciences.
“Both organizations have collaborated extensively over the past 25 years and share the same approach to customer service and flexibility—our company structure allows for quick responses and accommodates last-minute changes easily. ITR and Altasciences already have worked together to provide Bioanalytical services for complex analysis on preclinical studies that will then extend to the clinical programs,” said Ginette Bain, senior vice president at ITR Laboratories Canada.
The alliance provides clients a single, coordinated team throughout the drug development process, minimizing delays and time lost during the transition from nonclinical to clinical development. In addition, the partnership will provide clients guidance that leverages both ITR’s and Altasciences’ experience, knowledge, location and close working relationship throughout the process.